Literature DB >> 18629652

When drug companies select what they want to publish patients are denied relevant therapeutic information.

Graziella Filippini1, Lorenzo Moja, Alessandro Liberati, Gian Franco Gensini, Roberto Gusinu, Andrea A Conti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18629652     DOI： 10.1007/s11739-008-0174-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  12 in total

Review 1.  [Roaming through the methodology. XIV. The premature ending of a randomized trial].

Authors:  J P Vandenbroucke
Journal:  Ned Tijdschr Geneeskd       Date:  1999-06-19

Review 2.  Intention-to-treat principle.

Authors:  V M Montori; G H Guyatt
Journal:  CMAJ       Date:  2001-11-13       Impact factor: 8.262

3.  The evaluation of the results of clinical trials: surrogate end points and composite end points.

Authors:  G F Gensini; A A Conti
Journal:  Minerva Med       Date:  2004-02       Impact factor: 4.806

4.  Impugning the integrity of medical science: the adverse effects of industry influence.

Authors:  Catherine D DeAngelis; Phil B Fontanarosa
Journal:  JAMA       Date:  2008-04-16       Impact factor: 56.272

Review 5.  Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Authors:  P Rieckmann; K V Toyka; C Bassetti; K Beer; S Beer; U Buettner; M Chofflon; M Götschi-Fuchs; K Hess; L Kappos; J Kesselring; N Goebels; H-P Ludin; H Mattle; M Schluep; C Vaney; U Baumhackl; T Berger; F Deisenhammer; F Fazekas; M Freimüller; H Kollegger; W Kristoferitsch; H Lassmann; H Markut; S Strasser-Fuchs; K Vass; H Altenkirch; S Bamborschke; K Baum; R Benecke; W Brück; D Dommasch; W G Elias; A Gass; W Gehlen; J Haas; G Haferkamp; F Hanefeld; H-P Hartung; C Heesen; F Heidenreich; R Heitmann; B Hemmer; T Hense; R Hohlfeld; R W C Janzen; G Japp; S Jung; E Jügelt; J Koehler; W Kölmel; N König; K Lowitzsch; U Manegold; A Melms; J Mertin; P Oschmann; H-F Petereit; M Pette; D Pöhlau; D Pohl; S Poser; M Sailer; S Schmidt; G Schock; M Schulz; S Schwarz; D Seidel; N Sommer; M Stangel; E Stark; A Steinbrecher; H Tumani; R Voltz; F Weber; W Weinrich; R Weissert; H Wiendl; H Wiethölter; U Wildemann; U K Zettl; F Zipp; R Zschenderlein; G Izquierdo; A Kirjazovas; L Packauskas; D Miller; B Koncan Vracko; A Millers; A Orologas; M Panellus; C J M Sindic; M Bratic; A Svraka; N R Vella; Z Stelmasiak; K Selmaj; H Bartosik-Psujik; K Mitosek-Szewczyk; E Belniak; A Mochecka; A Bayas; A Chan; P Flachenecker; R Gold; B Kallmann; V Leussink; M Mäurer; K Ruprecht; G Stoll; F X Weilbach
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

6.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

7.  Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group.

Authors:  D E Goodkin; D Cookfair; K Wende; D Bourdette; P Pullicino; B Scherokman; R Whitham
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

8.  International consensus statement on the use of disease-modifying agents in multiple sclerosis.

Authors:  M S Freedman; L D Blumhardt; B Brochet; G Comi; J H Noseworthy; M Sandberg-Wollheim; Sørensen P Soelberg
Journal:  Mult Scler       Date:  2002-02       Impact factor: 6.312

9.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422
View more
  1 in total

Review 1.  The conundrum of iron in multiple sclerosis--time for an individualised approach.

Authors:  Susan J van Rensburg; Maritha J Kotze; Ronald van Toorn
Journal:  Metab Brain Dis       Date:  2012-03-17       Impact factor: 3.584
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.